

xNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514

Provisional Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|--|
| Company | General |
| Bayer (finerenone) | All Wales Therapeutics and Toxicology |
| | Centre |
| Patient/carer groups | Allied Health Professionals Federation |
| Arrhythmia Alliance | Board of Community Health Councils in |
| Atrial Fibrillation Association | Wales |
| Blood Pressure UK | British National Formulary |
| Cardiac Risk in the Young (CRY) | Care Quality Commission |
| Cardiomyopathy UK | Department of Health - Northern Ireland |
| Cardiovascular Care Partnership | Healthcare Improvement Scotland |
| Circulation Foundation | Medicines and Healthcare products |
| Heart Valve Voice | Regulatory Agency |
| Network of Sikh Organisations | National Association of Primary Care |
| Pumping Marvellous Foundation | National Pharmacy Association |
| Somerville Foundation | NHS Confederation |
| South Asian Health Foundation | NHS Wales Joint Commissioning |
| Specialised Healthcare Alliance | Committee |
| · | Scottish Medicines Consortium |
| Healthcare professional groups | Welsh Government |
| British and Irish Hypertension Society | |
| British Association for Nursing in | Possible comparator companies |
| Cardiovascular Care | Accord Healthcare (furosemide) |
| British Cardiovascular Society | ADVANZ Pharma (furosemide) |
| British Geriatrics Society | AS Kalceks (furosemide) |
| British Heart Foundation | AstraZeneca (dapagliflozin) |
| British Heart Rhythm Society | Baxter Healthcare (furosemide) |
| British Nuclear Cardiology Society | Boehringer Ingelheim (empagliflozin) |
| British Society for Heart Failure | Hameln Pharmaceuticals (furosemide) |
| British Society of Cardiovascular | Ipca Laboratories UK (furosemide) |
| Imaging | Mylan (bumetanide, torasemide) |
| National Heart and Lung Institute | Pinewood Healthcare (furosemide) |
| Primary Care Cardiovascular Society | Rosemont Pharmaceuticals |
| Royal College of Emergency Medicine | (bumetanide, furosemide) |
| Royal College of General Practitioners | Thame Laboratories (furosemide) |
| Royal College of Nursing | Tillomed Laboratories (furosemide) |
| Royal College of Pathologists | |

Provisional stakeholder list for the evaluation of finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514



| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|--|
| Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Cardiological Science & Technology Society for Vascular Nurses Society for Vascular Technology | Relevant research groups British Society for Cardiovascular Research Cardiac and Cardiology Research Dept, Barts Cochrane Heart, Stroke and Circulation Group |
| UK Clinical Pharmacy Association Vascular Society of Great Britain and Ireland | European Council for Cardiovascular Research Genomics England Heart Research UK |
| OthersDepartment of Health and Social CareNHS England | MRC Clinical Trials Unit National Centre for Cardiovascular Preventions and Outcomes National Institute for Health Research Wellcome Trust |
| | Associated Public Health groupsPublic Health WalesUK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514

Issue date: May 2025





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.